Cited by 424Lipid metabolism and disordersLipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI: evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo

Open access

Ginsberg, H N, Le, N A, Goldberg, I J, Gibson, J C, Rubinstein, A, Wang-Iverson, P, Norum, R, Brown, W V·1986·Journal of Clinical Investigation

DOI 10.1172/jci112713PMC PMC423815

Open this paper in CoChat — free account Open PDF

Abstract

Previous data suggest that apolipoprotein (apo) CIII may inhibit both triglyceride hydrolysis by lipoprotein lipase (LPL) and apo E-mediated uptake of triglyceride-rich lipoproteins by the liver. We studied apo B metabolism in very low density (VLDL), intermediate density (IDL), and low density lipoproteins (LDL) in two sisters with apo CIII-apo AI deficiency. The subjects had reduced levels of VLDL triglyceride, normal LDL cholesterol, and near absence of high density lipoprotein (HDL) cholesterol. Compartmental analysis of the kinetics of apo B metabolism after injection of 125I-VLDL and 131I-LDL revealed fractional catabolic rates (FCR) for VLDL apo B that were six to seven times faster than normal. Simultaneous injection of [3H]glycerol demonstrated rapid catabolism of VLDL triglyceride. VLDL apo B was rapidly and efficiently converted to IDL and LDL. The FCR for LDL apo B was normal. In vitro experiments indicated that, although sera from the apo CIII-apo-AI deficient patients were able to normally activate purified LPL, increasing volumes of these sera did not result in the progressive inhibition of LPL activity demonstrable with normal sera. Addition of purified apo CIII to the deficient sera resulted in 20-50% reductions in maximal LPL activity compared with levels of activity attained with the same volumes of the native, deficient sera. These in vitro studies, together with the in vivo results, indicate that in normal subjects apo CIII can inhibit the catabolism of triglyceride-rich lipoproteins by lipoprotein lipase.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1172/jci112713

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O. H., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 316,394
The metabolism of very low density lipoprotein proteins I. Preliminary in vitro and in vivo observations
Bilheimer, D. W., Eisenberg, S., & Levy, R. I. (1972) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(72)90034-3 · Cited by 1,815
Simple liquid-liquid partition system for isolation of labeled oleic acid from mixtures with glycerides
Belfrage, P., & Vaughan, M. M. (1969) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43094-9 · Cited by 765
Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins].
Sniderman, A. D., Shapiro, S., Marpole, D. G. F., Skinner, B., Teng, B., & Kwiterovich, P. O. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.1.604 · Cited by 632
Suppression by diets rich in fish oil of very low density lipoprotein production in man.
Nestel, P. J., CONNOR, W. E., Reardon, M., Connor, S. L., Wong, S., & Boston, R. C. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111422 · Cited by 616
Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein
Brown, W. V., & Baginsky, M. L. (1972) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(72)80149-9 · Cited by 493
Self-citation
Biology of Endothelial Cells
(1984) · Developments in cardiovascular medicine · doi:10.1007/978-1-4613-2825-4 · Cited by 427
Cholesterol in high-density lipoprotein: use of Mg2+/dextran sulfate in its enzymic measurement.
Finley, P. R., Schifman, R. B., Williams, R. J., & Lichti, D. A. (1978) · Clinical Chemistry · doi:10.1093/clinchem/24.6.931 · Cited by 418
Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. Opposing effects of homologous apolipoprotein E and individual C apoproteins.
Windler, E., Chao, Y., & Havel, R. J. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70647-4 · Cited by 365
Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat.
Shelburne, F. A., Hanks, J., Meyers, W., & Quarfordt, S. H. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109710 · Cited by 358

Show all 38 references

Research works printed but not linked: 1

Lipid Research Clinics Program. 1974. Lipid and Lipoprotein Analysis. Manual of Laboratory Operations. Vol. 1 National Institutes ofHealth, Bethesda, MD. Department ofHealth, Education, and Welfare Publication No. 75-628.

Sorted by citations

Items 301–400 of 424

The apolipoprotein CIII T2854G variants are associated with postprandial triacylglycerol concentrations in normolipidemic Korean men
Woo, S.-K., & Kang, H. (2003) · Journal of Human Genetics · doi:10.1007/s10038-003-0074-7 · Cited by 12
“For example, apo CIII inhibits lipoprotein lipase, a key enzyme hydrolyzing the triacylglycerol (TAG) portion of TRL, resulting in a delayed removal of TRL in vitro (Wang et al. 1985) and in vivo (Ginsberg et al. 1986).”
Background
Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here
Hermel, M., Lieberman, M., Slipczuk, L. N., Rana, J. S., & Virani, S. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020459 · Cited by 11
“Apo C-III inhibits the breakdown of triglyceride-rich lipoproteins by lipoprotein lipase [82,83].”
Background
Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 polymorphism
Aragonès, G., Alonso‐Villaverde, C., Pardo-Reche, P., Rull, A., Beltrán‐Debón, R., Rodríguez‐Gallego, E., Fernández-Sénder, L., Camps, J., & Joven, J. (2011) · BMC Medical Genetics · doi:10.1186/1471-2350-12-120 · Cited by 11
“Other functions attributed to apo C-III include a reduction in the hepatic uptake of apo B-containing lipoproteins [7,8] as well as an increase in the catabolism of high-density lipoprotein (HDL) particles [9], adhesion of monocytes to vascular endothelial cells [10], and the activation of inflammatory signaling pathw…”
Background
Reduced Reverse Cholesterol Transport Efficacy in Healthy Men with Undesirable Postprandial Triglyceride Response
Motte, A., Gall, J., Salem, J., Dasque, E., Lebot, M., Frisdal, É., Galier, S., Villard, E. F., Bouaziz-Amar, É., Lacorte, J., et al. (2020) · Biomolecules · doi:10.3390/biom10050810 · Cited by 12
“It is ell esta lis e t t III cts s i i it r f li r tei li se re s ecific ll i i its t e li r tei li s - i t li l sis of TG-rich lipoproteins [28].”
Background
Apolipoprotein CIII and Angiopoietin-like Protein 8 are Elevated in Lipodystrophy and Decrease after Metreleptin
Lightbourne, M., Wolska, A. T., Abel, B. S., Rother, K. I., Walter, M. F., Kushchayeva, Y. S., Auh, S., Shamburek, R. D., Remaley, A. T., Muniyappa, R., et al. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa191 · Cited by 11
“ApoC-III also has LPL-independent effects to increase triglycerides [31, 40], including inhibition of TRLP remnant uptake [32, 41, 42].”
Background
Lipids and atherosclerosis
Halpern, M. J. (1995) · Molecular Aspects of Medicine · doi:10.1016/0098-2997(95)00004-6 · Cited by 11
ApoE2-associated hypertriglyceridemia is ameliorated by increased levels of apoA-V but unaffected by apoC-III deficiency
Gerritsen, G., van der Hoogt, C. C., Schaap, F. G., Voshol, P. J., Kypreos, K. E., Maeda, N., Groen, A. K., Havekes, L. M., Rensen, P. C. N., & van Dijk, K. W. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800009-jlr200 · Cited by 11
Transient triglyceridemia in healthy normolipidemic men increases cellular processing of large very low density lipoproteins by fibroblasts in vitro
Björkegren, J., Karpe, F., Vitols, S., Tornvall, P., & Hamsten, A. (1998) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33903-1 · Cited by 10
Apolipoprotein C-III
Miller, M. J. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309493 · Cited by 10
Apolipoprotein-CIII O-Glycosylation, a Link between GALNT2 and Plasma Lipids
Naber, A., Demus, D., Slieker, R. C., Nicolardi, S., Beulens, J. W. J., Elders, P. J. M., Lieverse, A. G., Sijbrands, E. J. G., Hart, L. M. ‘., Wuhrer, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914844 · Cited by 9
“Apo-CIII inhibits lipoprotein lipase [4] and hepatic lipase [5], which regulate triglyceriderich lipoprotein (TRL) metabolism [6].”
Background
Integrin β3 Deficiency Results in Hypertriglyceridemia via Disrupting LPL (Lipoprotein Lipase) Secretion
Xiao, B., Mao, J., Sun, B., Zhang, W., Wang, Y., Wang, P., Ruan, Z., Xi, W., Li, H., Zhou, J., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.313191 · Cited by 9
JCL roundtable: Apolipoproteins as causative elements in vascular disease
Brown, W. V., Sacks, F. M., & Sniderman, A. D. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.10.003 · Cited by 9
Self-citation
Apolipoprotein CIII polymorphism and triglyceride levels of a Japanese population living in Southern Brazil
Parzianello, L., Oliveira, G., & Coelho, J. C. (2008) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2008005000022 · Cited by 9
“The genetically determined deficiency of apo-CIII has been shown to increase the rate of TG clearance from plasma by 6- to 7-fold (31).”
Background
Liver proteomic response to hypertriglyceridemia in human-apolipoprotein C-III transgenic mice at cellular and mitochondrial compartment levels
Ehx, G., Gérin, S., Mathy, G., Franck, F., Oliveira, H. C. F., Vercesi, A. E., & Sluse, F. E. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-116 · Cited by 9
“Apolipoprotein C-III (ApoC-III) is a glycoprotein component of TG-ric h lipoproteins (mainly very-low density lipoproteins, VLDLs) which is involved in the control of TG metabolism in human [4] and mouse [5].”
Background
1 Lipid transport through the plasma: the metabolic basis of hyperlipidaemia
Shepherd, J., & Packard, C. J. (1987) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(87)80021-6 · Cited by 9
Hyperlipidemia and cardiovascular disease: cardiovascular update
Le, N. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32830f4a57 · Cited by 8
Self-citation
Associations between apolipoprotein CIII concentrations and microalbuminuria in type 2 diabetes
Hu, Z., Ren, L., Wang, C., Liu, B., & Song, G. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.1830 · Cited by 8
“In the blood circulation, ApoCIII is associated mainly with TRLs, HDLs and, to a lesser extent, low-density lipoproteins (LDLs) (6-8).”
Influential
Lack of evidence for a liver or intestinal miRNA regulation involved in the hypertriglyceridemic effect of APOC3 3′UTR variant SstI
Dancer, M. S., Caussy, C., Filippo, M. D., Moulin, P., Marçais, C., & Charrière, S. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.10.024 · Cited by 9
Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D
Basu, A., Jenkins, A. J., Stoner, J. A., Zhang, Y., Klein, R. L., Lopes-Virella, M. F., Garvey, W. T., Schade, D. S., Wood, J., Alaupovic, P., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.p080143 · Cited by 8
“Quantification of Apo-C-III bound to Apo-A- and to Apo-B-containing lipoproteins was performed on heparin–manganese supernatants (Apo-C-IIIHS) and precipitates (Apo-C-III-HP), respectively (14).”
Background
Nucleotide sequences of the Macaca fascicularis apolipoprotein C-III and A-IV genes
Osada, J., Pocovı́, M., Nicolosi, R. J., Schaefer, E. J., & Ordovás, J. M. (1993) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(93)90226-4 · Cited by 8
Modulation of the expression of human LDL-Apo B-100 epitopes by lipids and apolipoproteins.
Harduin, P., Tailleux, A., Fruchart, J., & Fiévet, C. (1993) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.13.4.529 · Cited by 8
Distribution of CII and CIII peptides in lipoprotein classes: methods and clinical significance
Graziani, M. S., Zanolla, L., Righetti, G., Marchetti, C., Zanotto, G., & Lupo, A. (1994) · Clinical Chemistry · doi:10.1093/clinchem/40.2.240 · Cited by 8
Genetically determined increase in apolipoprotein C-III (APOC3 gain-of-function) delays very low-density lipoprotein clearance in humans
Packard, C. J., Taskinen, M., Björnson, E., Matikainen, N., Söderlund, S., Andersson, L. K., Adiels, M., & Borén, J. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119166 · Cited by 7
Probucol
Davignon, J. (1994) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-78426-2_15 · Cited by 7
Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects
Filippatos, T. D., Liontos, A., Christopoulou, E. C., & Elisaf, M. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180209112351 · Cited by 7
Is APOC3 the driver of cardiovascular disease in people with type I diabetes mellitus?
Ginsberg, H. N., & Reyes‐Soffer, G. (2019) · Journal of Clinical Investigation · doi:10.1172/jci131333 · Cited by 7
Self-citation
Distinct patterns of heparin affinity chromatography VLDL1 and VLDL2 subfractions in the different dyslipidaemias
Duvillard, L., CASLAKE, M. J., Petit, J., Vergès, B. L., Gambert, P., & Packard, C. J. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.11.026 · Cited by 7
Apolipoprotein C-III SstI Genotypes Modulate Exercise-Induced Hypotriglyceridemia
Woo, S.-K., & Kang, H. (2004) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000128200.38372.82 · Cited by 7
“Apo C-III inhibits lipoprotein lipase, a key enzyme in hydrolyzing the TG portion of TG-rich lipoproteins (TRL), and thereby results in a delayed removal of TRL in vitro (37) and in vivo (15).”
Background
The Effect of APOC3 Promoter Polymorphisms on the Risk of Hypertriglyceridemia in Chinese Han Population With or Without Type 2 Diabetes Mellitus
Yu, J., Wang, H., Yang, S.-M., Yuan, J., Chen, L., Chen, C. L., Huang, D. F., Wang, Y., Ju, S.-Q., & ZHU, J.-Y. (2009) · Laboratory Medicine · doi:10.1309/lmubypdivgqwoy2u · Cited by 7
The 3′-Flanking Region Shared by the Human Apolipoprotein AI and CIII Gene Regulates Gene Expression in Cooperation with 5′-Flanking Elements
HAASE, A., & STOFFEL, W. (1990) · Biological Chemistry Hoppe-Seyler · doi:10.1515/bchm3.1990.371.1.375 · Cited by 7
Emerging agents targeting triglycerides
Prakash, Y. S., Bhatt, D. L., & Malick, W. A. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000979 · Cited by 7
Life is complicated: so is apoCIII
Reyes‐Soffer, G., & Ginsberg, H. N. (2019) · Journal of Lipid Research · doi:10.1194/jlr.c119000214 · Cited by 6
“Lipoprotein kinetic studies of two sisters with complete absence of apoCIII (5) demonstrated, in vivo, that absence of this protein resulted in a dramatic increase in lipolysis of VLDL-TG (6).”
BackgroundSelf-citation
Treatment of the metabolic syndrome by siRNA targeting apolipoprotein CIII
Recio-López, P., Valladolid‐Acebes, I., Hadwiger, P., Hoßbach, M., Krampert, M., Prata, C. A. H., Berggren, P., & Juntti‐Berggren, L. (2022) · BioFactors · doi:10.1002/biof.1885 · Cited by 6
Overexpression ofapoC-III produces lesser hypertriglyceridemia in apoB-48-only gene-targeted micethan in apoB-100-only mice
Conde‐Knape, K., Okada, K., Ramakrishnan, R., & Shachter, N. S. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400185-jlr200 · Cited by 6
Tryptophan probes reveal residue-specific phospholipid interactions of apolipoprotein C-III
Pfefferkorn, C. M., Walker, R. L., He, Y., Gruschus, J. M., & Lee, J. C. (2015) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2015.08.018 · Cited by 6
Apolipoprotein-defined and NMR lipoprotein subclasses in the Veterans Affairs Diabetes Trial
Azar, M., Lyons, T. J., Alaupovic, P., Stoner, J. A., Quiroga, C., Kaufman, D., Lopes-Virella, M. F., Klein, R. L., & Jenkins, A. J. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.05.005 · Cited by 5
Malnourishment affects gene expression along the length of the small intestine
Pinho, R. M., Garas, L. C., Huang, B. C., Weimer, B. C., & Maga, E. A. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.894640 · Cited by 4
“Its absence has been shown to increase lipolysis of very-low-density lipoprotein (49, 50), indicating an increase in lipolysis in Mal animals, corroborating with the decrease of CIDEA/PLIN1 discussed previously.”
Result
Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study
Katakura, Y., Shimoda, M., Ohnishi, M., Kusano, T., Dan, K., Isobe, H., Wamata, R., Iwamoto, Y., Fushimi, Y., Sanada, J., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.02.011 · Cited by 5
Lipoprotein lipase in rat heart—II. influence of apolipoproteins and nutritional factors on tri- di- and monoacylglycerol lipase activities in post-heparin effluents
Vérine, A., Benkirane, M., Meignen, J. M., & Boyer, J. (1989) · Comparative Biochemistry and Physiology Part B Comparative Biochemistry · doi:10.1016/0305-0491(89)90004-7 · Cited by 5
Apo B-containing lipoprotein particles in poorly controlled insulin-dependent diabetes
Igau, B., Lestavel, S., Barthelemy-Clavey, V., Slomianny, C., Drouin, P., Bresson, R., Fruchart, J., Duriez, P., & Fiévet, C. (1996) · Atherosclerosis · doi:10.1016/0021-9150(95)05711-0 · Cited by 5
Lipids and its Metabolism
Bhatt, K. (2017) · Journal of Cardiology & Cardiovascular Therapy · doi:10.19080/jocct.2017.04.555635 · Cited by 4
“h) C-III-Interferes with apo-E mediated clearance of triglyceride-enriched lipoproteins and remnants by cellular receptors, particularly in the liver [10] inhibits triglyceride hydrolysis by lipoprotein lipase and hepatic lipase [11] has multiple proatherogenic effects on the arterial wall, including interfering with…”
Background
Role of growth hormone in hepatic and intestinal triglyceride-rich lipoprotein metabolism
Maraninchi, M., Calabrese, A., Nogueira, J. P., Castinetti, F., Mancini, J., Mourre, F., Pietri, L., Benamo, E., Albarel, F., Morange, I., et al. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.08.003 · Cited by 4
Triglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk
Bharadiya, V. M., Rawal, S., Jain, V., Chevli, P. A., & Mehta, A. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00702-1 · Cited by 5
Triglyceride-Rich Lipoproteins
Le, N., & Brown, W. V. (2010) · Springer eBooks · doi:10.1007/978-1-4419-5839-6_4 · Cited by 5
Self-citation
Insulin Resistance and Dyslipidemia
Chahil, T. J., Reyes, G., & Ginsberg, H. N. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-116-5_11 · Cited by 4
Self-citation
Lipoproteins: A Source of Cardiac Lipids
Drosatos, K., & Goldberg, I. J. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1227-8_2 · Cited by 4
Self-citation
Changes in lipoproteins induced by the remnant kidney tissue or binephrectomy in chronic uremic patients treated by hemodialysis
Robert, D., Jeanmonod, R., Favre, H., Fruchart, J., Sturzenegger, E., & Riesen, W. (1989) · Metabolism · doi:10.1016/0026-0495(89)90210-2 · Cited by 4
Apolipoprotein C3 Promotes Angiogenesis in an Inflammatory Mouse Model of Peripheral Artery Disease
Thomas, J., Bamhare, P. M., Mulangala, J., Bursill, C. A., Nicholls, S. J., Bartolo, B. A. D., & Bubb, K. J. (2025) · The FASEB Journal · doi:10.1096/fj.202502155r · Cited by 3
“ApoC3 partly inhibits triglyceride catabolism through lipoprotein lipase (LPL)–dependent and LPL-independent pathways [17].”
Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR Trials
Ballantyne, C. M., Baass, A. W., Rosenson, R. S., Hegele, R. A., Nicholls, S. J., Vasas, S., Clifton, P. M., Lucas, K. J., Páll, D., Zhou, R., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101523 · Cited by 3
“Apolipoprotein C ‑ III (APOC3), a protein primarily produced in the liver, regulates TRL metabolism by inhibiting lipoprotein lipase and impairing hepatic TRL clearance via LPL ‑ independent and -dependent mechanisms [13 – 16].”
Clinical use of genetic typing in human lipid disorders†
Brown, W. V., Breslow, J. L., & Ballantyne, C. M. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.02.007 · Cited by 3
Self-citation
Developments in understanding bile acid metabolism
Morimoto, K., Itoh, H., & 渡辺, 光. (2012) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.12.75 · Cited by 3
Apolipoprotein C-III can specifically bind to hepatic plasma membranes
Fang, D. Z., & Liu, B. W. (2000) · Molecular and Cellular Biochemistry · doi:10.1023/a:1007038129481 · Cited by 3
Exploration of Serum Marker Proteins in Mice Induced by Babesia microti Infection Using a Quantitative Proteomic Approach
Wang, X., Ren, S., Yang, X., Masoudi, A., Xue, X., Li, M., Li, H., Zhang, X., Wang, H., & Liu, J. (2021) · The Protein Journal · doi:10.1007/s10930-020-09952-7 · Cited by 3
A Lipid lover’s Guide to Novel Therapeutics for Lipid and Cardiovascular Risk Reduction
Hritani, R., Hussain, A., Saeed, A., & Agarwala, A. (2021) · Future Cardiology · doi:10.2217/fca-2020-0216 · Cited by 3
High dairy products intake modifies the correlation between α-tocopherol levels and serum proteins related to lipid metabolism in subjects at risk of type 2 diabetes
Mahdavi, A., Leclercq, M., Bodein, A., Gotti, C., Greffard, K., Bilodeau, J., Droit, A., Lebel, M., & Rudkowska, I. (2022) · Journal of Functional Foods · doi:10.1016/j.jff.2022.105375 · Cited by 3
Dietary fat saturation distinctly affects apolipoprotein gene expression and high density lipoprotein size distribution in two strains of Golden Syrian hamsters
Smith, D. E., Ahn, Y.-S., Pedro‐Botet, J., Osada, J., Mata, P., Schaefer, E. J., & Ordovás, J. M. (2001) · Nutrition Research · doi:10.1016/s0271-5317(00)00265-7 · Cited by 3
Nitric oxide-releasing agent, LA419, reduces atherogenesis in apolipoprotein E-deficient mice
Carnicer, R., Guillén, N., Arbonés-Mainar, J. M., Navarro, M. Á., Guzmán, M., Barranquero, C., Arnal, C., Gascón, S., Acı́n, S., Mourelle, M., et al. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0377-5 · Cited by 3
Production of Apolipoprotein C-III Knockout Rabbits using Zinc Finger Nucleases
Yang, D., Zhang, J., Xu, J., Zhu, T., Fan, Y., Fan, J., & Chen, Y. E. (2013) · Journal of Visualized Experiments · doi:10.3791/50957-v · Cited by 3
Familial Hypocholesterolemia and HDL Deficiency
Dumon, M. F., Freneix-Clerc, M., Maviel, M. J., & Clerc, M. (1990) · Advances in experimental medicine and biology · doi:10.1007/978-1-4684-5904-3_21 · Cited by 3
Characterization of Apolipoproteins B‐100, AI and C from Plasma Lipoprotein in the Goose, Anser anser
Hermier, D., Sellier, N. N., Rousselot-Pailley, D., & Forgez, P. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.586_b.x · Cited by 3
Apolipoprotein B Secretion Assay from Primary Hepatocytes
Wang, Y., Li, X., Huang, R., Chen, X.-W., & Wang, X. (2024) · BIO-PROTOCOL · doi:10.21769/bioprotoc.4982 · Cited by 2
No Apparent Impact of Meal Glycemic Index on Postprandial Lipid Response in Lean and Abdominally Obese Women
Silliman, K. (2012) · The Open Nutrition Journal · doi:10.2174/1874288201206010097 · Cited by 2
Howard's villa. Howard Hughes Medical Institute, Chevy Chase, MD.
Bierman, M. L. (1994) · PubMed · Cited by 2
Lipoproteins and Apoproteins
Citkowitz, E., & Herbert, P. N. (1999) · Developments in cardiovascular medicine · doi:10.1007/978-1-4615-5007-5_3 · Cited by 2
Population Semiphysiologic Kinetic Modeling and Simulation of Plasma Triglyceride Levels After Soybean Oil–Based Intravenous Lipid Emulsion Administration in Rats
Okada, A., Hirano, M., Tanioka, M., Tsujimoto, T., Koyama, H., Nishimura, A., Shibata, N., Fukushima, K., & Sugioka, N. (2016) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607116661030 · Cited by 3
Oligonucléotide antisens de l’apolipoprotéine C-III : nouveau traitement de certaines hypertriglycéridémies sévères
Valéro, R. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.06.013 · Cited by 2
Working towards full eradication of lipid-driven cardiovascular risk?
Nurmohamed, N. S., & Stroes, E. S. G. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01600-8 · Cited by 2
The Pancreas and Lipoprotein Metabolism
Ginsberg, H. N., & Goldberg, I. J. (2001) · Comprehensive physiology · doi:10.1002/cphy.cp070222 · Cited by 2
Self-citation
Hypolipidemic Effect of Peroxisome Proliferators
Hertz, R., Bishara-Shieban, J., & Bar‐Tana, J. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb18683.x · Cited by 2
Visceral Adiposity and Apolipoprotein C-III in Apolipoprotein B-Containing Lipoproteins Are Independent Predictors in Determining Atherogenic Lipid Profiles
Han, T., Woo, S.-K., Shin, S., & Kang, H. (2005) · Annals of Nutrition and Metabolism · doi:10.1159/000089562 · Cited by 2
“Although the precise mechanism of the hypertriglyceridemia has yet to be established, it appears to be implicated with elevated levels of apoC-III bound to apoB-containing lipoproteins (LpB:C-III) in circulating plasma secondary to either hepatic oversecretion or impaired lipolysis of triglyceride (TG)-rich lipoprotei…”
Background
Reduction in neutrophil elastase concentration by recombinant α1-antitrypsin (recAAT) does not alter bacterial loading in the sputum of cystic fibrosis patients
Moore, J. E., Shaw, A., Millar, B. C., Martin, L., Murphy, P. G., Downey, D. G., Ennis, M., & Elborn, J. S. (2004) · British Journal of Biomedical Science · doi:10.1080/09674845.2004.11732661 · Cited by 1
Pathophysiology of adipose tissue metabolism and atherosclerosis in familial combined hyperlipidemia
Ylitalo, K. (2001) · Työväentutkimus Vuosikirja · Cited by 2
Bile Acids and Metabolic Syndrome
Taoka, H., & 渡辺, 光. (2017) · Springer eBooks · doi:10.1007/978-4-431-56062-3_15 · Cited by 1
Dyslipidemia is the hallmark of the metabolic syndrome in postmenopausal women
Osman, A., & Fadlalla, A. M. (2020) · Annals of Medical Physiology · doi:10.23921/amp.2020v4i2.115684 · Cited by 1
“In the presence of insulin resistance the visceral adipocytes fail to respond to lipolytic effect of insulin, so that large amount of free fatty acids released into the hepatic cells leading to disproportionate production of TG and TG rich VLDLs [14] which consequently leads to increased production of apo-B — the majo…”
Background
Obesity versus endurance exercise training: plasma triacylglycerol and muscle lipoprotein lipase activity at the crossroads of lipid accumulation in muscle
Johnsson, K. A., George, J., Parks, E. J., & Katsanos, C. S. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00162.2025 · Cited by 1
629 ANTIRETROVIRAL TREATMENT-INDUCED DYSLIPIDEMIA IN HIV-INFECTED PATIENTS IS INFLUENCED BY THE APOC3-RELATED RS10892151 POLYMORPHISM
Beltrán‐Debón, R., Aragonès, G., Alonso‐Villaverde, C., Rull, A., Rodríguez, E., Pardo, P., Camps, J., & Joven, J. (2011) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(11)70630-4 · Cited by 1
The Isolation of Flowing Mesenteric Lymph in Mice to Quantify In Vivo Kinetics of Dietary Lipid Absorption and Chylomicron Secretion
Dedousis, N. L., Teng, L., & Kohan, A. B. (2022) · Journal of Visualized Experiments · doi:10.3791/64338 · Cited by 2
The Isolation of Flowing Mesenteric Lymph in Mice to Quantify In Vivo Kinetics of Dietary Lipid Absorption and Chylomicron Secretion
Dedousis, N. L., Teng, L., & Kohan, A. B. (2022) · Journal of Visualized Experiments · doi:10.3791/64338-v · Cited by 1
Atherosclerosis is the outcome of adaptive complexity in the Arterial Endothelial Microenvironment
Roy, T., Ray, A. G., & Bandyopadhyay, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00081-5 · Cited by 1
iTRAQ‑based quantitative proteomics analysis of the potential application of secretoneurin gene therapy for cardiac hypertrophy induced by DL‑isoproterenol hydrochloride in mice
Chen, H., Wu, M., Jiang, W., Liu, X., Zhang, J., & Yu, C. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4472 · Cited by 1
Options and Alternatives
Paquette, J. (2017) · Routledge eBooks · doi:10.4324/9781315225456-5 · Cited by 1
Metabolic and genetic determinants of HDL in families with low HDL cholesterol and premature coronary heart disease
Soro‐Paavonen, A. (2004) · Työväentutkimus Vuosikirja · Cited by 1
ApoC-III helical structure determines its ability to bind plasma lipoproteins and inhibit Lipoprotein Lipase-mediated triglyceride lipolysisPreprint
Vitali, C., Stankov, S. G., Khetarpal, S. A., Millar, J. S., Mayne, L. C., Englander, S. W., Hand, N. J., Lund‐Katz, S., Phillips, M. C., & Rader, D. J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.02.183178 · Cited by 1
Lipoprotein distribution of Apo CIII glycoforms in healthy men is linked with low TG and increased insulin sensitivityPreprint
Rodríguez, M. M., Rehues, P., Iranzo, V., Mora, J. D., Balsells, C., Guardiola, M., & Ribalta, J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.15.298802 · Cited by 1
Effect of non-esterified fatty acids on insulin resistance and cardiovascular risk in polycystic ovary syndrome
Aye, M. M. (2013) · Repository@Hull (Worktribe) (University of Hull) · Cited by 1
Serum proteins in type 1 diabetes
Shalaly, N. D. (2007) · Figshare
Alteraciones del metabolismo de las lipoprote?nas. Mecanismos etiopatog?nicos. Consecuencias fisiopatol?gicas
García-Andrade, C. R., Walther, L. A. L.-S., & Nez-Corts, J. M. (2008) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(08)73234-x
Lipoprotein Metabolism and Vascular Biology
Choi, B. G., Badimón, J. J., Moreno, P., & Fuster, V. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-533-6_1
“• Lipoprotein metabolism has two main pathways: ( 1 ) the exogenous pathway that starts with intestinal absorption of dietary fat and cholesterol and (2) the endogenous pathway that starts with hepatic VLDL production.”
BackgroundInfluential
[Gender differences and diabetic status in the relationship of blood apolipoprotein C-III, free fatty acids and triglycerides in subjects at risk for glucose intolerance].
Florez, H. J., Méndez, A. J., Jones, L. A., & Goldberg, R. B. (1999) · PubMed
Simvastatin/fenofibrate combination in the treatment of dyslipidemia: current evidence
Jimenez, J. G., & Haft, G. (2014) · Research and Reports in Endocrine Disorders · doi:10.2147/rred.s50952
Le rôle de ses activateurs dans la régulation de l'expression des gènes impliqués dans le métabolisme des lipoprotéines, l'inflammation vasculaire et l'athérosclérose
Duriez, P., Staels, B., & Fruchart, J. (2000) · Annales de l Institut Pasteur / Actualités · doi:10.1016/s0924-4204(00)80018-9
Transport des lipides
Perret, B., Milne, R. W., & Collet, X. (2000) · Annales de l Institut Pasteur / Actualités · doi:10.1016/s0924-4204(00)80014-1
Novel factors affecting clearance of triacylglycerol-rich lipoproteins from blood
Nilsson, S. K. (2010)
Dyslipidemia in Diabetes Mellitus and Chronic Kidney Disease
Krikorian, A., & Chaiban, J. T. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0793-9_12
Role Of Lipid Concentrations and Apolipoproteins In Altering ApoB Metabolism and Promoting Coronary Events
Sacks, F. M. (2000) · Springer eBooks · doi:10.1007/978-4-431-68424-4_2
Apolipoprotein C-III, An Important Player in Lipoprotein Metabolism
Fruchart, J., Barthelemy-Clavey, V., Luc, G., Dallongeville, J., Staels, B., & Auwerx, J. H. (1996) · Medical science symposia series · doi:10.1007/978-94-009-0311-1_74
Mendel, Molecular Biology, and Apolipoprotein C-III: A Heady Combination
Patel, S. B. (2015) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.1506
“4,5 This, combined with in vitro studies from several sources as well as mouse models, led to the concept that the functional role of ApoCIII is to inhibit lipoprotein and hepatic lipases.”
syndromeof dyslipidaemia in the metabolic
Kolovou, G. D., Anagnostopoulou, K. K., & Cokkinos, D. V. (2006)
Lipoprotein lipase and apolipoprotein E polymorphisms : relationship to hypertriglyceridemia associated with pregnancy
McGladdery, S. H. (2009) · cIRcle (University of British Columbia) · doi:10.14288/1.0089570
Studies on lipoprotein kinetics in obesity and the metabolic syndrome: impact of dietary weight loss and statin therapy
Ng, T. (2007) · UWA Profiles and Research Repository (UWA)

Authors: Ginsberg, H. N., Le, N. A., Goldberg, I. J., Gibson, J. C., Rubinstein, A., Wang-Iverson, P., Norum, R., & Brown, W. V.
Affiliations: Columbia University Irving Medical Center (US)
Icahn School of Medicine at Mount Sinai (US)
Henry Ford Hospital (US)
ORCID: Ginsberg, H N
Le, N A
Goldberg, I J
Rubinstein, A
Venue: Journal of Clinical Investigation
Publisher: American Society for Clinical Investigation
Published: 1986-11-01
Volume: 78
Issue: 5
Pages: 1287-1295
ISSN: 0021-9738 (ISSN-L)
DOI: 10.1172/jci112713
PMC: PMC423815
OpenAlex: W2057271976
Cited by: 424
References: 38
Citations by year: 2026: 4 · 2025: 5 · 2024: 5 · 2023: 7 · 2022: 11 · 2021: 15 · 2020: 23 · 2019: 9 · 2018: 15 · 2017: 18 · 2016: 12 · 2015: 18 · 2014: 11 · 2013: 14 · 2012: 8
FWCI: 4.39
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Investigation (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health
National Heart, Lung, and Blood Institute (HL-23077, HL-00949)
National Center for Research Resources (RR 71)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords: apolipoprotein C-III, apolipoprotein A-I deficiency, lipoprotein lipase inhibition, triglyceride-rich lipoproteins, VLDL, IDL, low-density lipoprotein, fractional catabolic rate, lipoprotein catabolism, lipoprotein lipase activation
MeSH terms: Adult, Apolipoproteins A, Apolipoproteins B, Apolipoproteins C, Cholesterol, Humans, Hypolipoproteinemias, Kinetics, Lipoprotein Lipase, Lipoproteins, LDL, Lipoproteins, VLDL, Models, Biological, Triglycerides, Apolipoprotein A-I, Apolipoprotein C-II

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI: evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks